About the Global CEO Initiative on Alzheimer’s Disease
The Global CEO Initiative on Alzheimer’s Disease (CEOi) is convened by UsAgainstAlzheimer's and is a collaboration of leading private sector organizations dedicated to accelerating progress in the fight against Alzheimer's disease. By leveraging the collective influence of its members, CEOi works to shape global dialog, drive innovations in diagnostics and treatment, and increase global awareness of Alzheimer's.
Collaborative Workgroups Pushing Alzheimer’s Diagnostic Knowledge Forward
BBM Workgroup
Our Mission
To prepare for the widespread adoption of blood-based biomarkers in clinical practice to enable a more simple, timely, and accurate diagnostic experience for patients.
90+ Participants
The BBM Workgroup attracted more than 90 participants, including experts from healthcare, academia, non-profit, government, venture capital, industry, and patient advocacy.
DCA Workgroup
Our Mission
To prepare for the adoption of digital cognitive assessments in clinical care so patients experience a more simple, timely, and accurate diagnostic experience
200+ Participants
The DCA Workgroup attracted more than 200 participants with a diverse array of backgrounds, including experts from health systems, academia, industry, digital health, diagnostic vendor organizations, patient advocacy, and payers.
